|
|
Vaccine Detail
|
TARP 27-35 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: TARP 27-35 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007047
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TARP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for various cancers (NCT00972309). A peptide-based cancer vaccine, containing amino acid residues 27 through 35 of T cell receptor gamma alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 27-35 peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic (Wood et al., 2016; NCIT_C85462).
|
| Host Response |
|
|
| References |
NCIT_C85462: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85462]
NCT00972309: [https://clinicaltrials.gov/show/NCT00972309/]
Wood et al., 2016: Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. Oncoimmunology. 2016; 5(8); e1197459. [PubMed: 27622067].
|
|
